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Macrophage and dendritic cell (DC) are hematopoietic cells found in all tissues in the steady state that share
the ability to sample the environment but have distinct function in tissue immunity. Controversies remain on
the best way to distinguish macrophages from DCs in vivo. In this Perspective, we discuss how recent
discoveries in the origin of the DC andmacrophage lineage help establish key functional differences between
tissue DC andmacrophage subsets.We also emphasize the need to further understand the functional hetero-
geneity of the tissue DC and macrophage lineages to better comprehend the complex role of these cells in
tissue homeostasis and immunity.History of the Discovery of the Mononuclear
Phagocyte System
In 1908, ElieMetchnikoff (1845–1916), together with Paul Ehrlich,
was awarded the Nobel Prize for his work on phagocytosis
(Kaufmann, 2008). Metchnikoff classified phagocytes (named
after the Greek ‘‘phago’’ for devour and ‘‘cytes’’ for cells) into
‘‘macrophages’’ (large eaters) and ‘‘microphages’’ (a smaller
type of phagocytic cell, the polymorphonuclear leukocyte now
known as granulocytes) and argued that both types of phago-
cytes played an important role in host resistance against infec-
tions. Metchnikoff also recognized the close relationship
between mononuclear phagocytic cells in the spleen, lymph no-
des, bone marrow, and connective tissues, leading him to intro-
duce for the first time the term ‘‘macrophage system’’ (Gordon,
2008). Karl Albert Ludwig Aschoff, a German physician and
pathologist, developed this concept further and grouped several
cell types into what he called the reticulo-endothelial system and
subsequently the reticulo-histiocyte system. The reticuloendo-
thelial system included reticular cells (or fixed macrophages) of
the spleen and lymph nodes, endothelial cells of the lymph and
blood sinuses, monocytes, and histiocytes, a term referred to
as ‘‘tissue wandering as opposed to fixed’’ macrophages. These
cells were grouped on the basis of their capacity to uptake vital
dye in vivo, an assay thought to measure phagocytic activity.
However, poorly phagocytic cells, such as endothelial cells
can also become labeled as a result of pinocytosis, especially
when large amounts of dye are applied. Such labeling is there-
fore unreliable as a criterion for the identification of mononuclear
phagocytes and a new classification was devised in 1969 to
group only highly phagocytic cells and their precursors in one
system called the mononuclear phagocyte system (MPS),
a term that is still in use today (van Furth et al., 1972).
In the early 1970s, Ralph Steinman and Zanvil Cohn identified
a population of hematopoietic cells in the mouse spleen that
excel at antigen presentation and T cell stimulation, named
dendritic cells (DCs) (Steinman and Cohn, 1973, 1974). Similar
to macrophages, DCs are derived from hematopoietic progeni-
tors and populate most lymphoid and nonlymphoid tissues.
Initially thought to be poorly phagocytic, there is now evidencethat DCs have a potent phagocytic activity that is mostly dedi-
cated to inform the adaptive immune system about peripheral
tissue cues through their unique ability to sample tissue anti-
gens, migrate to the draining lymph nodes, present extracellular
antigens, and initiate tissue-specific T cell immunity (Mellman
and Steinman, 2001).
Accumulating evidence now suggests that macrophages and
DCs are tissue phagocytic cells that specialize in the sensing and
sampling of the tissue environment. Although the term MPS has
created a framework that helped our understanding of tissue
phagocyte biology, it also led to the assumption that all tissue
phagocytes are identical in origin and function. Here, we
describe the limitation of the MPS definition and its failure to
account for the heterogeneous origin of tissue phagocytes. We
also argue that defining DC and macrophage population on the
basis of their origin should help understand the discrete role of
these cells in tissue immunity and homeostasis.
Heterogeneity of Tissue-Resident DCs
DCs are classified into two main subsets that include classical
DCs and plasmacytoid DCs (Heath and Carbone, 2009).
Because the main theme of this Perspective is to discuss tissue
phagocyte heterogeneity, plasmacytoid DCs will not be dis-
cussed here, considering that the ability of these cells to popu-
late nonlymphoid tissues in the steady state as well as to phago-
cytose, process, and present extracellular tissue antigens is
limited (Villadangos and Young, 2008).
Classical DCs (referred to as DCs here) form a heterogeneous
population of hematopoietic cells that reside in all lymphoid,
interface, and connective tissues (Figure 1). One of the biggest
challenges to understand themolecularmechanisms that control
DC function has been the lack of specific markers to define the
DC lineage. DCs continue to be defined to date as hematopoietic
cells lacking hematopoietic lineage markers while expressing
high amounts of MHC class II (shared by B cells and activated
macrophages) and the integrin CD11c (also expressed by some
macrophage population, activated T cells, B cells and NK cells).
Progress has been made in recent years in understanding
the origin and the transcriptional program that control DCImmunity 35, September 23, 2011 ª2011 Elsevier Inc. 323
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Figure 1. Origin of Batf3-IRF8-Id2-Dependent and -Independent Tissue-Resident DCs in Mice
Lymphoid and peripheral tissues have at least four distinct resident DC subsets: CD4CD8a+, CD4+CD8a, CD103+CD11b, and CD103CD11b+ DCs. A
CD103+CD11b+ DC subset has been best characterized within the small intestine. This figure illustrates the precursors, transcription factors (black), and cytokine
receptors (red) required for the development of each population. Commitment to the mononuclear phagocyte lineage is determined at the stage of the
macrophage-dendritic cell progenitor (MDP). Granulocyte/macrophage progenitor (GMP) give rise to MDP, which has lost granulocyte potential and gives rise
only to monocytes and DCs restricted precursors (common DC precursors [CDPs]). CDPs have lost monocyte-macrophage differentiation potential and give rise
exclusively to plasmacytoid DCs (pDCs) and pre-DCs circulating precursors that migrate to lymphoid tissues where they differentiate into lymphoid tissue
CD4CD8a+ and CD4+CD8a DCs and to nonlymphoid tissue to give rise to CD103+CD11b DCs and CD103+CD11b+ DCs. Flt3 controls myeloid precursors
commitment to the DC lineage as well as the differentiation of mature DCs in tissue. The transcription factors Batf3 Id2 and IRF8 control the differentiation of
lymphoid tissue CD8+ DC and nonlymphoid tissues CD103+CD11b DC but do not control CD11b+ DC differentiation in lymphoid and nonlymphoid tissues.
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enous cell populations that derive from committed precursors
along a distinct differentiation program shifting the focus from
studies on phenotypically defined subsets to developmentally
regulated subsets. Belowwediscuss the importance of revisiting
the role of DCs by separating the contribution of these develop-
mentally distinct DC subsets in tissue immunity.
The Batf3-IRF8-Id2 DC Lineage
The Batf3-IRF8-Id2 DC lineage refers to a group of DCs located
in lymphoid and non-lymphoid tissues that share a common
origin, phenotype and function.
Lymphoid Tissue CD8+ DCs and Nonlymphoid Tissue
CD103+CD11b– DCs Have a Common Origin
As shown in Figure 1, the presence in lymphoid tissues of
a discrete population of DCs that expressed the CD8aa homo-
dimer but lacked the CD8b chain and CD11b marker, most
commonly referred to as CD8+ DCs, has been known for more
than a decade (Shortman and Heath, 2010). Several studies
have now established that CD8+ DCs arise from a distinct differ-
entiation program that is dependent on key transcription factors
that include Batf3 (Hildner et al., 2008) and IRF8 (Aliberti et al.,
2003; Schiavoni et al., 2002; Tailor et al., 2008) and the inhibitor
of DNA protein Id2 (Hacker et al., 2003). Absence of any of these
factors prevents the differentiation of CD8+ DCs in lymphoid
organs, but does not affect the differentiation of CD8 DCs
(Hacker et al., 2003; Hildner et al., 2008; Tailor et al., 2008).
Data have also shown that the mammalian target of rapamycin324 Immunity 35, September 23, 2011 ª2011 Elsevier Inc.(mTOR), promotes the differentiation of CD8+ DCs and that the
loss of the tumor suppressor gene PTEN, a negative regulator
of mTOR, expands the number of CD8+ DCs in murine lymphoid
tissues (Sathaliyawala et al., 2010).
A DC subset equivalent to lymphoid tissue CD8+ DCs has
been identified in nonlymphoid tissues. These cells lack the
CD8 marker and express the integrin CD103 (Bedoui et al.,
2009; del Rio et al., 2007; Sung et al., 2006). Similar to CD8+
DCs, they express low amounts CD11b (del Rio et al., 2007;
GeurtsvanKessel et al., 2008; Sung et al., 2006) and lack macro-
phage markers such as CD172a, F4/80, and CX3CR1 (Ginhoux
et al., 2009). Nonlymphoid tissue CD103+CD11b DCs share
the same differentiation requirements as CD8+ DCs. They are
absent in Batf3-deficient (Edelson et al., 2010), Id2-deficient
(Ginhoux et al., 2009; Edelson et al., 2010) and IRF8-deficient
mice (Ginhoux et al., 2009) and expand in PTEN-deficient mice
(Sathaliyawala et al., 2010). Of note, CD103 is not a specific
marker of Batf3-IRF8-Id2-dependent DCs as CD103 is also ex-
pressed on a subset of CD11b+ DCs in the lamina propria
(Coombes et al., 2007; Jaensson et al., 2008; Johansson-Lind-
bom et al., 2005; Sun et al., 2007). Lamina propria
CD103+CD11b+ DCs develop normally in Batf3-deficient and
IRF8 deficient mice (Edelson et al., 2010) and in Id2-deficient
mice (M. Bogunovic, F. Ginhoux and M.M., unpublished data)
as discussed below.
Importantly, lymphoid tissue CD8+ DCs and nonlymphoid
tissue CD103+CD11b DCs, which will be referred to as Batf3-
IRF8-Id2 DCs in this Perspective, are critically dependent on
Table 1. Dendritic Cell Heterogeneity
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This table summarizes published data on differential expression of Toll-
like receptors (Edwards et al., 2003; Luber et al., 2010; Yarovinsky
et al., 2005), lectin-like receptors (Dudziak et al., 2007; Shortman and
Heath, 2010), and other cell markers (Dorner et al., 2009; Galibert et al.,
2005; Ginhoux et al., 2009; Lahoud et al., 2006; Shortman and Heath,
2010) between Batf3-IRF8-Id2 dependent DCs (including CD8+ and/or
CD103+ DCs) and Batf3-IRF8-Id2- independent DCs.
Immunity
Perspectivethe cytokine fms-like thyrosine kinase 3 ligand (Flt3L) and its
receptor (Flt3) for their development and homeostasis (Figure 1,
Table 1). Flt3 and Flt3L are key regulators of DC commitment in
hematopoiesis. Flt3 is expressed on short-term repopulating
hematopoietic stem cells and is progressively extinguished on
most hematopoietic cell lineages with the exception of the DC
precursors (Merad and Manz, 2009). Loss of Flt3 expression in
hematopoietic progenitors correlateswith the lossofDCdifferen-
tiation potential, whereas enforcement of Flt3 expression on
Flt3-negative progenitors rescues their ability to differentiate
into DC (Onai et al., 2006). Flt3 expression is maintained in
lymphoid tissue DCs and Flt3L has been shown to control the
proliferation and homeostasis of DCs in lymphoid organs (Liu
et al., 2007; Waskow et al., 2008). Importantly, nonlymphoid
tissue CD103+CD11b DCs also express high amounts of Flt3
receptor on the cell surface and are more severely reduced in
mice reconstituted with Flt3-deficient hematopoietic progenitorscompared to CD103 DCs or tissue macrophages (Ginhoux
et al., 2009). It is interesting to note that in bone marrow chimeric
mice reconstituted with Flt3-deficient hematopoietic progeni-
tors, CD103+CD11bDCsare completely absent in nonlymphoid
tissue whereas CD8+ DCs are reduced by one-third in lymphoid
tissues (Ginhoux et al., 2009). These results are likely to reflect
the more stringent role of Flt3 in maintaining DC homeostasis in
nonlymphoid tissues compared to lymphoid organs.
In contrast, lymphoid tissue CD8+ DCs and nonlymphoid
tissue CD103+CD11b DCs lack the receptor for colony stimu-
lating factor 1 (Csf-1), a cytokine that controls the differentiation
of many tissue macrophages in vivo (Chitu and Stanley,
2006) and remain unaffected in mice that lack Csf-1 receptor
(Csf-1R) and in mice that are reconstituted with Csf-1 receptor
(Csf-1R)-deficient hematopoietic progenitors (Ginhoux et al.,
2009).
Lymphoid tissue CD8+ DCs and nonlymphoid tissue
CD103+CD11b DCs are derived from DC-restricted precursors
that have been identified in mice blood and bone marrow.
Commitment to the mononuclear phagocyte lineage is deter-
mined at the stage of the macrophage-dendritic cell progenitor
(MDP) (Auffray et al., 2009; Fogg et al., 2006), at which point,
erythroid, megakaryocyte, lymphoid, and granulocyte fates
have been precluded. MDPs give rise to monocytes and DCs
restricted precursors (also called common DC precursors
[CDPs]), which have lost monocyte-macrophage differentiation
potential. CDPs give rise exclusively to plasmacytoid DCs and
pre-DCs, circulating precursors that migrate to lymphoid tissues
where they differentiate into lymphoid tissue CD8+ and CD8
DCs (Naik et al., 2007; Onai et al., 2007). Subsequent studies
revealed that pre-DCs also migrate to nonlymphoid tissues
and give rise to nonlymphoid tissue CD103+CD11b DCs but
also to CD103+CD11b+ DCs (Bogunovic et al., 2009; Ginhoux
et al., 2009; Varol et al., 2009) (Figure 1).
Interestingly, Batf3 Id2 and IRF8 are differentially expressed
along the DC lineage (Edelson et al., 2010; Jackson et al.,
2011). IRF8 gene is expressed in DC-restricted precursors in
the bone marrow and remained expressed in circulating precur-
sors and in terminally differentiated CD8+ and CD103+ DC
subsets, whereas its expression is extinguished in lymphoid
tissue-resident CD8 DCs, which also derive from DC-restricted
precursors (Edelson et al., 2010; Jackson et al., 2011). Reporter
mice and expression array data revealed that Id2 is absent in
DC-restricted precursors in the bone marrow, starts to be ex-
pressed in pre-DCs that reach the spleen, increases in all DC
subsets but reach higher amounts in CD8+ and CD103+ DCs
(Edelson et al., 2010; Jackson et al., 2011). In contrast, Batf3
gene becomes expressed only in the terminal stages of DC
development and is highly expressed by all DCs (Edelson
et al., 2010; Jackson et al., 2011). The overlap of high IRF8,
Id2, and Batf3 expression was only found within the CD8+ and
CD103+ DC subsets, strongly suggesting that it is the combina-
tion of these three factors that controls the differentiation and/or
function of lymphoid tissue CD8+ DCs and nonlymphoid tissue
CD103+CD11b DCs.
CD8+ and CD103+CD11b– DCs Share a Similar Gene
Expression Pattern and a Similar Sensing Repertoire
Transcriptional analysis of purified lymphoid tissue CD8+ and
nonlymphoid tissue CD103+CD11b DCs isolated from differentImmunity 35, September 23, 2011 ª2011 Elsevier Inc. 325
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(Edwards et al., 2003; Edelson et al., 2010) (see also www.
immgen.org). Lymphoid tissue-resident CD8+ DCs share several
sensing receptors with nonlymphoid tissue CD103+CD11b
DCs. For example, lymphoid tissue CD8+ DCs are the only
lymphoid tissue DCs expressing toll-like receptor 3 (TLR3) and
TLR11- TLR12 but they lack TLR7 (Edwards et al., 2003; Short-
man and Heath, 2010; Yarovinsky et al., 2005). Similarly, skin
migratory CD103+CD11b DCs are the only migratory DCs
expressing TLR3 (Jelinek et al., 2011); they also express high
amounts of TLR11 transcripts and lack TLR7. Lymphoid tissue
CD8+ DCs also lack the retinoic acid inducible gene (RIG-I),
a sensor required to sense certain viruses in the cytoplasm
(Luber et al., 2010), and similarly, RIG-I transcripts are expressed
at much lower levels in nonlymphoid tissue CD103+CD11bDCs
compared to other nonlymphoid tissue DC (www.immgen.org)
(Table 1).
Lymphoid tissue CD8+ DCs express the lectin-like receptors
CD207 and CD205, and the recently described Clec9A special-
ized in the sensing of necrotic bodies, whereas these lectins
are absent or expressed at lower amounts in CD8DCs (Dudziak
et al., 2007; Sancho et al., 2009; Shortman and Heath, 2010).
Similarly, nonlymphoid tissue CD103+CD11b DCs express
CD205 and can express CD207 at least in some tissues including
skin and lung, whereas CD207 is always absent from lung and
skin CD103CD11b+ DCs (Helft et al., 2010) . Our unpublished
data also suggest that Clec9A is expressed specifically by
nonlymphoid tissue CD103+CD11b DC and is absent from
CD103CD11b+ DC isolated from the same tissues.
Lymphoid tissue CD8+ DCs (Dorner et al., 2009) and nonlym-
phoid tissue CD103+CD11b DCs (J. Helft and M.M., unpub-
lished data) also uniquely express the chemokine receptor
XCR1.
CD8+andCD103+CD11b–DCsShareaCommonFunction
Lymphoid tissue CD8+ DCs and nonlymphoid tissue CD103+
CD11b DCs are very potent at producing interleukin-12 (IL-12),
cross-presenting antigens toCD8+ T cells, and inducing the differ-
entiation of effector CD8+ T cells (Sung et al., 2006; del Rio et al.,
2007; GeurtsvanKessel et al., 2008; Henri et al., 2010; Kim and
Braciale, 2009; Bedoui et al., 2009; Heath and Carbone, 2009;
Shortman and Heath, 2010). The GTPase Rac2 specifically ex-
pressed by CD8+ DCs and absent from CD8 DCs is thought to
control antigen processing and cross-presentation through the
regulation of phagosomal pH and oxidation (Savina et al., 2006;
Savina et al., 2009). Although likely, it remains to be determined
whether a similar machinery is also in place in nonlymphoid tissue
CD103+CD11b DCs. The increased ability to interact with CD8+
T cellswas also recently shown tobedependent on theexpression
of XCR1, a chemokine receptor which ligand XCL1 is produced by
naive CD8+ T cells (Dorner et al., 2009). XCR1 is restricted to
lymphoid tissue CD8+ DCs (Dorner et al., 2009) and nonlymphoid
tissue CD103+CD11b DCs (unpublished data) and is absent
from Batf3-IRF8-Id2 independent DCs.
In agreement with their unique TLR3 expression, CD8+ DCs
and CD103+CD11b DCs share a superior ability to respond to
TLR3 ligand adjuvant (Hochrein et al., 2001; Jelinek et al., 2011;
Longhi et al., 2009; Sung et al., 2006). In addition, recent data
revealed that CD8+ DCs are also the only lymphoid tissue DC
subset that produces interferon lambda in response to the326 Immunity 35, September 23, 2011 ª2011 Elsevier Inc.TLR3 ligand Poly: I:C (Lauterbach et al., 2010), and similar results
were found for lung CD103+CD11b DC (unpublished data).
Overall, these results show that Batf3-IRF8-Id2-dependent
DCs regardless of their tissue localization share a similar origin,
differentiation program, sensing repertoire, and T cell stimulatory
function, suggesting that at least some diversity of the DC
lineage is determined at the precursor stage.
Batf3-IRF8-Id2 DC Equivalent in Humans
and Other Species
In comparison to mice DCs, considerably less is known about
the origin of human DCs, their differentiation program and their
functional differentiation in situ due to their rarity in blood and
poor accessibility of human tissues, with the exception of the
skin. Circulating DC subsets have been distinguished based on
three cell surfacemarkers including CD1c (or BDCA1) expressed
on the majority of circulating DCs in humans, CD141 (also called
BDCA3) expressed on a minute population, and Fcg receptor III
(CD16) (Dzionek et al., 2000; Huysamen et al., 2008; Scha¨kel
et al., 2002; Ueno et al., 2010).
Similar to Batf3-IRF8-Id2-dependent DCs in mice, CD141+
CD1c DCs were found to uniquely express the lectin Clec9A
and the chemokine receptor XCR1 and excel in the production
of IL-12 and the cross-priming of CD8+ T effector cells (Bachem
et al., 2010; Crozat et al., 2010; Jongbloed et al., 2010; Lauter-
bach et al., 2010; Poulin et al., 2010). CD141+CD1c DCs were
also found to uniquely express TLR3 and to be the main
producers of interferon lambda in response to poly:I:C activation
(Lauterbach et al., 2010). However, the human CD1c+ DC
subset also shared some functional properties with mice
Batf3-IRF8-Id2 DCs given that they were found to produce
high amounts of IL-12 and to cross-prime antigens to CD8+
T cells (Mittag et al., 2011). Interestingly, the genetic analysis
of patients with disseminated mycobacterial infection identified
two distinct mutations affecting IRF8 transcriptional activity.
One mutation led to the complete depletion of DCs and circu-
lating monocytes (Hambleton et al., 2011). A distinct mutation
led to the specific depletion of circulating CD1c+ DCs, whereas
CD141+ DCs remained intact in these patients (Hambleton
et al., 2011). These results suggest that IRF8 transcription
factors also controls DC differentiation in humans but, in contrast
to mice IRF8, is also involved in the development of monocytes.
Further studies are required to fully understand the transcrip-
tional program that controls DC development in humans, which
could potentially differ frommice. More studies are also required
to further understand the functional heterogeneity of human
DC subsets and to assess whether the phenotypic markers
currently used to define these subsets in the blood help define
functionally distinct populations.
Interestingly, analysis of skin migratory DC isolated from
the sheep skin draining lymphatic vessels revealed that the
presence of a DC subset, which, similar to mouse Batf3-IRF8-
Id2 DCs, lacks the macrophage marker CD172a, expresses
high amounts of CD205, Clec9A, and XCR1, and excels in the
cross-presentation of soluble antigens and in the differentia-
tion of CD8+ effector T cells (Contreras et al., 2010). The
molecular program that controls the development of this func-
tional and phenotypically distinct DC subset remains to be
analyzed but if identical to mice, these results will support the
presence of an evolutionary conserved DC subset further
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tissue immunity.
The Batf3-IRF8-Id2-Independent DC Lineage
The Batf3-IRF8-Id2 independent DC lineage refers to DCs that
develop independently of Batf3, Id2, and IRF8. Phenotypically,
Batf3-IRF8-Id2 independent DCs are more heterogeneous than
Batf3-IRF8-Id2 -dependent DCs. Although they always express
CD11b and lack CD8, they are heterogenous for CD103,
CD172a, F4/80, and CX3CR1 expression (Ginhoux et al., 2009;
Helft et al., 2010). The transcription factors IRF4, IRF2 (Ichikawa
et al., 2004; Suzuki et al., 2004), and RBPJ (Caton et al., 2007)
partly control the differentiation of CD8 DCs in lymphoid
organs, but the molecular program that controls the differentia-
tion of Batf3-IRF8-Id2 -independent DCs in nonlymphoid tissues
needs to be clarified and the exact relationship between Batf3-
IRF8-Id2 -independent DCs in lymphoid versus nonlymphoid
tissues remains unclear.
The heterogeneity of Batf3-IRF8-Id2 independent DCs has
been most clearly identified in the lamina propria, where they
consist of two distinct DC populations best distinguished
on the basis of CD103 expression. Lamina propria Batf3-
IRF8-Id2 independent DCs include CD103+CD11b+ DCs and
CD103CD11b+ DC subsets. CD103+CD11b+ lamina propria
DCs express low amounts of the macrophage markers
CD172a, F4/80 and CX3CR1 and low Csf-1R. They express
high amounts of Flt3 receptor and are dependent on Flt3L and
GM-CSF (also called Csf-2) for their development, whereas
they are unaffected in Csf-1R deficient mice (Bogunovic et al.,
2009; Schulz et al., 2009; Varol et al., 2009). Adoptive transfer
studies of purified precursors revealed that lamina propria
CD103+CD11b+ DCs derive from DC-restricted precursors
(Bogunovic et al., 2009; Varol et al., 2009) and potently migrate
to the draining lymph nodes upon oral microbial stimuli (Bogu-
novic et al., 2009; Schulz et al., 2009).
In contrast, lamina propria CD103CD11b+ cells express the
macrophage markers CD172a, F4/80, CX3CR1, and the Csf-
1R. They are derived from circulating monocytes and not
from DC restricted precursors and require Csf-1R but not
Flt3, Flt3L, Csf-2, or Csf-2R for their development (Bogunovic
et al., 2009; Schulz et al., 2009; Varol et al., 2009). They are
much less potent than CD103+CD11b+ DCs at stimulating
T cell proliferation (Schulz et al., 2009) and migrate poorly to
the draining lymph nodes during oral infection (Bogunovic
et al., 2009; Ginhoux et al., 2009; Varol et al., 2009), suggesting
that this population despite expression of high MHC II and
CD11c, probably corresponds to tissue macrophages. Alto-
gether, CD103 expression helps decipher the heterogeneity
of Batf3-IRF8-Id2-independent CD11b+ DCs in the lamina
propria, which consists of CD103+CD11b+ DC and CD103
CD11b+ macrophages.
However, such markers are currently lacking in other tissues.
For example in the lung, CD11b+ DCs lack CD103 but are hetero-
geneous for macrophage markers and for the DC marker CD24.
They are partly reduced in mice reconstituted with Flt3/ or
Csf1r/ hematopoietic progenitors (Ginhoux et al., 2009), which
probably reflect the heterogeneity of this DC population. The use
of Flt3 or Csf-1R as markers of heterogeneity as well as other
profiling tools together with lineage tracing and functionalgenomic studies as discussed below should help clarify the
regulatory and functional attributes of this DC subset.
The Langerhans Cell Exception
Langerhans cells (LCs) refer to the DCs that reside in the
epidermal layer of the skin (Merad et al., 2008). These cells stand
apart from other tissue DCs because they have unique ontogeny
and homeostatic properties (Ginhoux and Merad, 2010). Pheno-
typically, LCs express lower MHC II, intermediate CD11c, and
very high amounts of the lectin receptor CD207, which is also
expressed, although at lower amounts, by Batf3-IRF8-Id2-
dependent DCs (Merad et al., 2008). They express CD11b,
F4/80 and lack CX3CR1 (Merad et al., 2008). In contrast to
most tissue DCs, they arise from embryonic precursors that
are recruited to the skin prior to birth and are maintained in the
skin throughout life in steady-state conditions (Chang-Rodriguez
et al., 2005; Chorro et al., 2009; Merad et al., 2002). LCs are
absent in Id2-deficient mice (Hacker et al., 2003) and have
been reported to be reduced in IRF8-deficient mice (Schiavoni
et al., 2004). However, epidermal LCs remained unaffected in
patients with mutations impairing IRF8 gene function (Hamble-
ton et al., 2011), which is consistent with our unpublished data
showing that epidermal LC are not reduced in numbers in
IRF8-deficient mice but express reduced MHC II levels.
In agreement with their distinct origin and homeostasis, LCs
express a very distinct gene expression pattern compared to
other DCs (www.immgen.org). In contrast to most DCs, LCs
lack Flt3 and develop independently of the DC cytokine Flt3
ligand but require Csf-1R but not Csf-1 for their development
(Ginhoux et al., 2006). These results came as a surprise given
that Csf-1R was thought to control mainly macrophage develop-
ment (Chitu and Stanley, 2006). In the epidermis, LCs are highly
phagocytic and have low MHC class II expression on the cell
surface, but migratory LC that reach the lymph nodes become
indistinguishable phenotypically from othermigratory DC (Merad
et al., 2008). LC are also thought to modulate skin contact hyper-
sensitivity response (Kaplan et al., 2005) and are required to
induce antigen specific T helper 17 cell differentiation in re-
sponse to skin candida albicans infection (Igya´rto´ et al., 2011).
In vitro studies using primary LCs isolated from mice and hu-
mans also suggest that LCs are very potent at initiating T cell
response and at cross-presenting cell-associated antigens (Kle-
chevsky et al., 2008; Stoitzner et al., 2008).
Monocyte-Derived DC and Tip DC
Monocytes can easily be differentiated into DCs in vitro (Sallusto
andLanzavecchia, 1994,) but theexactcontributionofmonocytes
to the DC pool in the steady state remains unclear. In contrast to
the steady state, monocyte differentiation into DC dramatically
increases in inflamed tissues. The term TNF-iNOS DC (Tip DC)
was first used to describe monocytes that differentiate into DCs
in the spleens of listeria-infected animals (Serbina et al., 2003).
Tip DCs were described as cells expressing Gr-1 (Ly6C),
CD163, intermediate MHC II, and the integrin CD11c and
producing TNF and iNOS (Serbina et al., 2003). This term was
subsequently extended to all inflammatory monocyte-derived
DCs without always providing supportive data showing TNF and
iNOS secretion. Recent studies identified new means to distin-
guishmonocyte-derivedDCs in inflamed lymphoid organs,whichImmunity 35, September 23, 2011 ª2011 Elsevier Inc. 327
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et al., 2010). The cytokines and transcription factors that control
monocyte-derived DC differentiation remain unclear. Csf-2,
a cytokine essential for the generation of in vitro-derived DCs, is
thought to be critical for the differentiation of inflammatory
DCs, although definite proof of the role of this cytokine in DC
differentiation in vivo remains to be established (Shortman and
Naik, 2007).
In Vitro-Derived DC
The identification of in vitro culture conditions that promote the
differentiation of DCs contributed substantially to the expansion
of the DC field (Caux et al., 1992; Inaba et al., 1992; Sallusto
and Lanzavecchia, 1994). In mice, bone marrow progenitors
represent themain source of in vitro-derived DCs, whereas in hu-
mans, DCs are generated from circulating monocytes or CD34+
hematopoietic progenitors. InDCcultures,Csf-2 is a keycytokine
to drive DC differentiation (Caux et al., 1992; Inaba et al., 1992;
Sallusto and Lanzavecchia, 1994). However, DC populations ob-
tained in Csf-2-driven cultures do not faithfully resemble DC
subsets identified in vivo. These results together with the realiza-
tion that Flt3L rather than Csf-2 drives DC differentiation in vivo
(Vremec et al., 1997) have led to substitution of Flt3L for Csf-2
in DC differentiation cultures (Naik et al., 2007). Bone marrow-
derived DCs cultured in the presence of Flt3L leads to the differ-
entiation of DC subsets that phenotypically and functionally
resemble CD8+ and CD8 DCs (del Rio et al., 2008; Naik et al.,
2007). Further analysis of these DC populations both at the tran-
scriptional and functional levels should help establish the physi-
ological relevance of this in vitro differentiation DC system.
Heterogeneity of Tissue Macrophages
Macrophages are hematopoietic cells that populate every tissue
including the brain. Whereas DCs are focused on initiating
tissue immune responses, macrophages main role is to ensure
tissue integrity. Functions shared by most tissue macrophages
include a high phagocytic function and degradative potential,
allowing them to clear foreign and damaged cells (Gordon and
Taylor, 2005). Macrophages also participate in the induction of
innate immunity in response to tissue infection, which plays a
critical role in the killing of micro-organisms and their pathogenic
factors (Gordon and Taylor, 2005). They can also load extracel-
lular antigen in MHC class II compartments but they are less effi-
cient than DCs at priming naive T cells and mostly interact with
effector CD4+ T cells. Different names have been used to identify
macrophage populations in vivo, which aremostly defined on the
basis of a set of defined cell surface markers (Table 2). These
names can reflect those of the scientists who discovered these
cells (i.e., Kupffer cells in the liver) or the location in which they
reside (i.e., marginal zonemacrophages and the red pulpmacro-
phages of the spleen, subcapsular sinus, and medullary macro-
phages in lymph nodes), but are rarely informative of the cells’
origin and function. Similar to DCs, the lack of genetic tools tar-
geting specifically the macrophage lineage compromises our
understanding of the regulatory mechanisms that control macro-
phage development and function in vivo. The recent develop-
ment of engineered mouse models to track, deplete, modify,
and alter the macrophage compartment will undoubtedly trans-
form our view of the macrophage lineage.328 Immunity 35, September 23, 2011 ª2011 Elsevier Inc.Regulation of Macrophage Development
Although the current dogma suggests that most tissue macro-
phages derive from circulating monocytes that originate in the
bone marrow, direct evidence that circulating monocytes con-
tribute to all tissue macrophages is lacking. Adoptive transfer
studies revealed that monocytes contribute to the red pulp
macrophages (Fogg et al., 2006) and the mucosal macrophage
(Varol et al., 2007; Bogunovic et al., 2009; Varol et al., 2009)
pool, but further studies are needed to confirm the contribution
of circulating monocytes to other tissue macrophage subsets.
There is now clear evidence that macrophages can proliferate
locally in the steady state and in response to specific tissue
injury, and the contribution of circulating precursors versus
self-renewal to tissue macrophage homeostasis remains to be
established (Gordon and Taylor, 2005; Jenkins et al., 2011; Ran-
dolph, 2011). The capacity of macrophage to self-renew and
contribute to their homeostasis highlights one of the limitations
of the MPS definition that suggests that all tissue phagocytes
are derived from a mobile pool of circulating monocytes.
The dramatic reduction of tissue macrophages observed in
Csf1r/mice, that lack theCsf-1R (Dai et al., 2002) andCsf1op/op
mice (Yoshida et al., 1990), that have a natural null mutation in the
Csf-1 cytokine gene, established the key role of Csf-1 and its
receptor in macrophage homeostasis in vivo (Pixley and Stanley,
2004). However, the precise role of Csf-1 and its receptor in
monocyte commitment remains controversial. One hypothesis
is that Csf-1 drives the differentiation of monocytes into tissue
macrophages (Metcalf, 1985), whereas a different hypothesis
suggests that Csf-1 provides a survival signal to the differenti-
ating monocytes and that surviving cells utilize an intrinsic devel-
opmental program to become mature macrophages (Korn et al.,
1973; Lagasse and Weissman, 1997; Nakahata et al., 1982).
Importantly, some tissue macrophages are more profoundly
affected in the absenceof Csf-1R than in the absenceof its ligand
Csf-1. For example, the brain resident macrophages, also called
microglia and the epidermal LCs, develop normally in Csf1op/op
mice but are absent in Csf1r/ mice (Ginhoux et al., 2010; Gin-
houx et al., 2006). Interestingly, a second CSF-1R ligand called
interleukin 34 (IL-34) has been identified (Lin et al., 2008). Evolu-
tionarily conserved IL-34 has been identified in humans, mice,
and birds (Garceau et al., 2010). IL-34 is highly expressed in the
brain of postnatal mice (Wei et al., 2010) and the exact role of
IL-34 in the development and homeostasis of microglia and other
tissue macrophages remains to be determined.
The transcriptional program that control monocyte-macro-
phage differentiation has been reviewed elsewhere (Auffray
et al., 2009; Friedman, 2007; Geissmann et al., 2010). However,
most of the studies on the transcriptional regulation of macro-
phage differentiation were done in vitro with progenitor-enriched
populations, and the exact role of these factors in driving the
differentiation of monocytes into distinct macrophage subsets
in vivo remains to be examined. This is particularly important
given that functional macrophage specialization is likely to be
regulated at the tissue levels and not at the progenitor level.
Functional Specialization of Tissue Macrophages
Although the developmental pathways that give rise to distinct
macrophage subsets are still unclear, there is evidence that
different macrophage populations play distinct roles in vivo. In
Table 2. Heterogeneity of Tissue Macrophages in Mice
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Spleen Lymph node Bone marrow Thymus
Red pulp MØ
-Entire red pulp
-F4/80hiCD11bloCD169loMHCIIlo
CD163+CD68+CD115+CD172a+
Marginal zone MØ
-Outer layer
of marginal zone sinus
-F4/80-SIGN-R1+MARCO+
Marginal zone metallophilic MØ
-Inner layer of marginal zone sinus
-F4/80-CD169+
Tingible body MØ
-Germinal center
-F4/80-CD11b-CD68+MFG-E8+
Subcapsular sinus MØ
-Lining subcapsular sinus
-F4/80loCD11b+CD169+CD11clo
MARCO+
Medullar MØ
-Lining medullar sinus
-F4/80hiCD11b+CD169+CD11clo
CD11chiCD169+ MØ
-Boundary between the sinus and
the T cell zone or B cell follicle
-MHCII+F4/80+CD169+CD11chiCD8+
Tingible body MØ
-Germinal center
-F4/80-CD11b-CD68+MFG-E8+
Subcapsular MØ
-MHCII+F4/80+Mac-2-FcγRII+FcγRIII+
Cortex MØ
-MHCII-F4/80+Mac-2+FcγRII+FcγRIII+
Cortico-medullary MØ
-MHCII+F4/80+Mac-2+
FcγRIIhiFcγRIIIhi
Medulla MØ
-Germinal center
-MHCIIhiF4/80+Mac-2+
FcγRII+FcγRIII+
Bone marrow CD169+  MØ
-Distributed throughout the
marrow but enriched around
the hematopoietic stem cell niche
-F4/80+CD11bloCD169+CD11clo
CD68+CX3CR1-CD115+
Phan et al., 2009
Asano et al., 2011
Chow et al., 2011
Crocker and Gordon, 1986
Soga et al., 1997Lloyd et al., 2008
Kohyama et al., 2009
Miyake et al., 2007
You et al., 2011
Hanayama et al., 2004
Rabinowitz et al., 1991
Lymphoid tissue macrophages
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Liver Lung Gut Skin Kidney
Kupffer cell
-In the liver sinusoid
-F4/80hiCD11bloCD169+
CD68+Mac-2+
Alveolar MØ
-Alveolar airspace
-F4/80+CD11bloCD169+
CD11chiCD68+SiglecF+
MARCO+Mac-2+
Interstitial MØ
-Alveolar interstitium
-CD11c-F4/80+CD68+
MHCII+
Lamina propria MØ
-Intestinal lamina propria
-MHCII+F4/80+CD11b+
CD11c+CD103-CD115+
CX3CR1+CD172a+
Dermal MØ
-F4/80+CD11b+CD11clo
mMGL+CD206+MHCIIlo
In deep dermis, 
MØ can express CD169+
KidneyMØ
-F4/80+CD11bloCD103-
CX3CR1+CD172a+
Serosal DC or MØ
-Intestinal muscular layer
and serosa
-MHCIIhiF4/80+CD11b+
CD169+CD11cloCX3CR1+
CD103-CD115+
Non-lymphoid tissue macrophages
Flotte et al., 1983
Kinoshita et al., 2010
Crocker and Gordon, 1989
Flotte et al., 1983
Tateno et al., 2007
Ducreux et al., 2009
Palecanda et al., 1999
Bedoret et al., 2009
Lagranderie et al., 2003
Bogunovic et al., 2009
Flores-Langarica et al., 2005
Dupasquier et al., 2004
Dupasquier et al., 2006
Our unpublished data
This table describes the name, localization, and phenotype of macrophage populations that reside in the spleen (Hanayama et al., 2004; Kohyama
et al., 2009; Lloyd et al., 2008; Miyake et al., 2007; Rabinowitz and Gordon, 1991; You et al., 2011), lymph nodes (Phan et al., 2009); (Asano et al.,
2011), bone marrow (Chow et al., 2011; Crocker and Gordon, 1986), thymus (Soga et al., 1997), liver (Crocker and Gordon, 1989; Flotte et al.,
1983; Kohyama et al., 2009), lungs (Bedoret et al., 2009; Ducreux et al., 2009; Flotte et al., 1983; Lagranderie et al., 2003; Palecanda et al., 1999; Tateno
et al., 2007), gut (Bogunovic et al., 2009; Flores-Langarica et al., 2005), and skin (Dupasquier et al., 2004; Dupasquier et al., 2006).
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Perspectivemost tissues, macrophages promote tumor surveillance through
their ability to capture and kill malignant hematopoietic cells
(Jaiswal et al., 2010), but can also promote tumor growth
through their ability to increase angiogenesis and immunosu-
pression (Qian and Pollard, 2010). Osteoclasts represent a pop-
ulation of bone macrophages that specialize in bone resorption
and are critical to maintain bone mass homeostasis (Edwards
and Mundy, 2011). Bone marrow macrophages promote the
retention of hematopoietic stem cells and the depletion of
bone marrow macrophages mobilizes hematopoietic progeni-
tors to the blood, enhancing yields of clinical mobilization
regimen for hematopoietic cell transplants (Chow et al., 2011).
In allogeneic hematopoietic cell transplant recipient, host
lymphoid tissue macrophages reduce the allogeneic T cell pool
and limit graft versus host reactions through their ability to
capture live allogeneic T cells and inhibit T cell proliferation (Ha-
shimoto et al., 2011). In lymph nodes, subcapsular macrophages
provide a key barrier that protects from the systemic dissemina-
tion of viruses (Iannacone et al., 2010) and promote the presenta-
tion of viral antigens to B cells (Phan et al., 2009; Phan et al.,
2007). These results emphasize the functional diversity of the
macrophage network, which may be partly dictated by the envi-
ronment in which the macrophage resides. In support of this
hypothesis are the findings showing that whereas Csf-1R and
the transcription factor PU.1 (Friedman, 2007) control the
commitment to a common macrophage program, the transcrip-
tion factors c-fos and MITF control specifically osteoclast differ-
entiation (Edwards and Mundy, 2011), and the transcription
factor Spi-C selectively controls the development of red pulp
macrophages but no other macrophage population (Kohyama
et al., 2009). Therefore, one of the biggest challenges in the
macrophage field is to continue to explore the origin of the
precursor cell population and themolecular program that control
global macrophage commitment in bone marrow progenitors,
but in addition, to decipher the regulatory program that controls
macrophage specialization and function in the periphery.
The Microglia Exception
Microglia cells (from the Greek ‘‘glia’’ for glue) refer to cells in
the brain that are nonneuronal and nonastrocytic playing a
supportive role in brain homeostasis. Although microglia share
many key features with other tissue macrophages, they have
a distinct origin in that they derive from embryonic precursors
that have been recruited to the brain prior to birth (Ransohoff
and Perry, 2009) . Using in vivo cell fate mapping studies, recent
data suggest that primitivemacrophages are themainprecursors
of adult microglia that populate the adult brain (Ginhoux and
Merad, 2010). In addition and in contrast to most adult tissue
macrophages, some studies have reported that microglia are
maintained throughout life independently of any blood input
and can resist high dose g-ray irradiation (Ajami et al., 2007;Mild-
ner et al., 2007), although arguments against this hypothesis have
also been presented (Soulet and Rivest, 2008). Similar results
were found for epidermal LCs (Merad et al., 2002). Importantly,
microglia and LCs can be repopulated by circulating monocytes
upon brain or skin injuries (Ginhoux et al., 2006; Mildner et al.,
2007).Whether embryonic-derived cells that populate the normal
skin and brain have a similar function to that ofmonocyte-derived
cells that arise in injured tissues remains to be examined.330 Immunity 35, September 23, 2011 ª2011 Elsevier Inc.Altogether, these results emphasize yet another limitation of
the MPS definition that suggests that two prominent populations
of phagocytes that reside in the brain and skin are in fact derived
from embryonic myeloid precursors and not from bone marrow-
derived monocytes.
Distinguishing DCs from Macrophages In Vivo
Most cells types in vivo are identified on the basis of their
ontogeny, phenotype, and function. In contrast, the definition
of tissue DCs and macrophages remains mostly phenotypic
and the use of the cell surface markers CD11c and F4/80 as
surrogate for origin and function have lead to confusion on the
exact contribution of DCs versus macrophages to tissue immu-
nity. Indeed, the CD11c integrin can be expressed on macro-
phages and monocytes, and therefore the role of CD11c+ cells
does not always reflect the role of DCs in vivo. Similarly, F4/80
is also expressed by eosinophils in the gut and neutrophils in
the bone marrow and is not a specific marker of macrophages.
Whereas differentiating macrophages from Batf3-IRF8-Id2-
independent MHCII+ CD11c+ cells continues to be difficult prob-
ably because these cells as currently defined are heterogeneous
and include tissue macrophages as discussed above, Batf3-
IRF8-Id2 DCs are easily distinguished from macrophages as
described above and summarized below.
1. Origin: Batf3-IRF8-Id2 DCs arise from CDP in an Flt3L-
dependent and Csf-1R ligand-independent manner,
whereas macrophages arise independently of CDP and
require Csf-1R ligand but not Flt3L for their development.
2. Phenotype: Batf3-IRF8-Id2 DCs lack Csf-1R, CD11b,
CX3CR1, F4/80, and CD172a, whereas macrophages
always express some or all of these markers.
3. Function: Batf3-IRF8-Id2 DCs are much more potent at
initiating T cell differentiation compared to macrophages.
Batf3-IRF8-Id2 DCs have a much lower degradative
potential compared to macrophages and excel in antigen
cross-presentation to CD8+ T cells, whereas macro-
phages can only cross-present very large amount of anti-
gens.
4. Migratory Potential : Batf3-IRF8-Id2 DCs are much more
potent in migrating to the draining LN compared to macro-
phages.
In sum, prior confusion on DCs and macrophages contribution
to tissue immunity is partly due to the fact that lineage mar-
kerMHCII+CD11c+cellsarenot synonymousofDCsandaneffort
to better define the heterogeneity of Batf3-IRF8-Id2-independent
MHCII+ CD11c+ cells is critically needed to help clarify the role of
these cells in the modulation of tissue immune responses.
Focusing on DCs and Macrophage Heterogeneity
Rather than Similarities
The termmononuclear phagocyte systemwas critical to alert the
scientific community of the importance of phagocytes in innate
immune defense. Stressing the commonality of a cellular system
widely distributed throughout the body to promote host defense
against foreign invasion facilitated the acceptance of a new
cellular lineage by the scientific community. More than a century
after their discovery, the identification of human diseases due to
Immunity
Perspectivecompromised phagocyte function together with the develop-
ment of mouse models with engineered phagocyte-specific
genetic defects established the key role of phagocytes in tissue
immunity and homeostasis. However, these studies have also
revealed the complexity and heterogeneity of this cellular
system. In fact, while Aschoff stressed the importance of a
certain fundamental resemblance between the cells with respect
to phagocytosis and storage, he insisted that similarities do not
amount to identity and expected that future research would
make it possible to distinguish more accurately between dif-
ferent populations of tissue phagocytes.
There have been controversies on whether cross-presenta-
tion function is unique to DCs, given that macrophages can
also cross-present extracellular antigens to CD8+ T lympho-
cytes if incubated with large amount of soluble antigens. Sub-
sequent studies using genetically engineered mouse models
revealed that absence of Batf3-IRF8-Id2-dependent DCs
abolishes the cross-presentation of cell-associated antigens
despite the presence of normal tissue macrophages (Hildner
et al., 2008). These results are consistent with in vitro studies
showing that macrophages are unable to cross-present limiting
amounts of soluble antigens. These data also suggest that in
considering differences among tissue phagocytes, it is critical
not only to assess the capacity of the cells to perform a function
but also the efficiency with which this function is performed.
Focusing on differences in cross-presentation among DCs and
macrophages has helped investigators identify pathways that
promoteDC superior ability to cross-present tissue antigens (Sa-
vina et al., 2006; Savina et al., 2009). These studies have also
helped the development of targeting strategies to promote
T cell immunity in vivo (Bonifaz et al., 2002; Bonifaz et al., 2004;
Ueno et al., 2011). There are also controversies onwhether tissue
cell migration to the draining lymph node is unique to DCs
becausemacrophages also canmigrate to tissue draining lymph
nodes in response to tissue injury, although this occurs at low
frequency, and thus its functional relevance is not known. DCs,
in contrast to macrophages, can migrate to the draining lymph
nodes in the absence of tissue injury, and steady state migration
to the lymph nodes and presentation of self-antigens provides
a mechanism to promote peripheral tolerance (Hemmi et al.,
2001; Huang et al., 2000; Mellman and Clausen, 2010; Ohl
et al., 2004; Pughet al., 1983) that could be exploited for the treat-
ment of autoimmunediseases (Steinmanet al., 2003).DCs’ ability
to migrate to the draining LN in response to tissue injury
augments many folds, is controlled in part by CCR7 ligands,
and is required to induce adaptive immune response to periph-
eral tissue antigens (Ohl et al., 2004; Randolph et al., 2008).
What Next in MPS Research?
Although we have highlighted the importance of acknowledging
phagocyte heterogeneity in vivo, it is critical to distinguish
between phenotypic plasticity and discretemononuclear phago-
cyte subsets. The definition of a mononuclear phagocyte subset
should only be based on developmental and functional evidence
and not on a set of phenotypical differences. System-wide inves-
tigation of gene expression at the mRNA transcript level should
help revisit phagocyte subset classification and identify gene
regulatory networks that control MPS development, differentia-
tion, and function. Quantitative proteomics also holds greatpromise to enhance or complement the picture of gene expres-
sion in cells, and thus to contribute to the understanding of tissue
phagocytes’ molecular program. The paucity of available tissue
phagocytes especially in nonlymphoid tissues remains, how-
ever, a great limitation.
System biology studies should also help the development of
genetic toolsallowing induciblegene regulation invivoand lineage
tracing of genetically marked, defined myeloid precursor popula-
tion to further comprehend the developmental complexity of the
phagocyte system. RNA interference (RNAi) is the most rapid
means to identify gene function in human and mouse cells. At
present, high-throughput screening is only feasible in cell culture,
which limits the approach to in vitro derived macrophage and DC
with the limitation discussed above as primary tissue phagocytes
cannot be easily manipulated in culture. However, as we learn
more about the developmental requirements of macrophages
andDCs, it shouldbepossible togeneratebetter invitroand invivo
models for performing gain- and loss-of-function studies. These
studies will then need to be validated in the human setting using
similar genetics approaches. Unraveling the transcriptional pro-
gram that controls macrophage and DC functional heterogeneity
will undoubtedly opensnewstrategies for takingMPSbiology into
medicine (Steinman and Banchereau, 2007).
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